Explore our resources by research/diagnostic specialty or content type

ALPCO specialists are leveraging their extensive expertise to create a growing collection of resources for your research and testing. Find resources that benefit your work using the handy filters.

Adipokines and Adipose Tissue-Liver Crosstalk in Energy Metabolism
February 6, 2018

Adipokines and Adipose Tissue-Liver Crosstalk in Energy Metabolism

Research over the past several decades examining adipokines and adipose tissue-liver crosstalk in energy metabolism has revealed that adipose tissue is a very important metabolically active endocrine organ1. White, brown, and beige adipose tissue generate and secrete adipokines, such as adiponectin and leptin, which facilitate adipose tissue-liver crosstalk and insulin sensitivity1. https://...
 Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week
May 2, 2017

New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®

We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac disease. Both assays specifically quantify levels of zonulin with no cross-reactivity to haptoglobin...
Adiponectin in NAFLD and NASH Research
March 7, 2017

The Impact of Adiponectin in NAFLD and NASH Research

Date: March 7, 2017 Lately, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been widely discussed in both the clinical and research communities. Some of the focus has been related to alternative research methods that can improve diagnostic and monitoring methodologies at the clinical level. These include more sophisticated imaging techniques as well as n...
Emerging Biomarker Research in NAFLD and NASH
February 21, 2017

Emerging Biomarker Research in NAFLD and NASH

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease in the western hemisphere affecting 1 in 3 adults and 1 in 10 children1.  Today, liver biopsies are the only gold standard for precise diagnosis of NAFLD2. Because of this, there are tremendous efforts on the research and clinical side to introduce newer, less invasive methodologies which will aid in diag...
Choosing the Relevant GLP-1 Species to Study
November 29, 2016

Choosing the Relevant GLP-1 Species to Study

  A better understanding of incretins has led to tremendous therapeutic advances in the field of type 2 diabetes1. These hormones are released from the gut in response to food ingestion and lead to the stimulation of pancreatic β-cells which then release insulin in a glucose-concentration dependent manner1. One such hormone is glucagon-like peptide-1 (GLP-1) that has been shown to initi...
Crytosporidium
November 15, 2016

Differentiating Gastrointestinal Pathogens from IBD and IBS

Gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as infections from GI pathogens can present very similar symptoms. A host of tests have been developed to aid in the differentiation between IBD and IBS, such as calprotectin and lactoferrin. However, there is still a need for more research to fully understand the process of diff...
Endocrine Disrupting Chemicals and Biomarkers of EDC
October 12, 2016

Endocrine Disrupting Chemicals and Biomarkers

Introduction Humans and the environment are exposed to numerous chemicals every day1. Each year, about 2,000 new chemicals are manufactured in the U.S.2. Research findings over the years have shown how some chemicals known as endocrine disrupting chemicals (EDCs) can interact with the endocrine system, disrupt homeostasis, and lead to issues such as obesity and sterility1. As a result, endocri...
Regulating Endocrine Disrupting Chemicals
September 27, 2016

Regulating Endocrine Disrupting Chemicals in Consumer Products

Date: September 27, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO From cosmetics to water bottles, endocrine disrupting chemicals (EDCs) have surfaced in our everyday lives. EDCs are compounds that can interfere with the endocrine system’s ability to help an organism develop, grow, reproduce, and maintain overall homeostasis1.  Since EDCs are found nearly everywhere, we...
The Benefits of Therapeutic Drug Monitoring for IBD
September 13, 2016

[Infographic] The Benefits of Therapeutic Drug Monitoring for IBD

The Burden of Inflammatory Bowel Disease in the US and Canada More than 1 million people in the US and 200,000 people in Canada are currently living with inflammatory bowel disease (IBD). This number is projected to grow exponentially over the next 10 years1,2. As the prevalence of IBD increases, so do direct healthcare costs. Between hospitalizations, surgery, ambulatory care and biologic the...
PI3K Delta Signaling in Rheumatoid Arthritis
September 6, 2016

PI3K Delta Signaling in Rheumatoid Arthritis

Date: September 6, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Signaling pathways dictate the differentiation, activation, and functions of immune cells.  Even the slightest problem in one cell signaling pathway can transform the immune system and turn it against the body, causing an autoimmune disease. Research has shown that proper phosphoinositide 3-kinase (PI3K) c...